DJS Antibodies
Oxford, United Kingdom
DJS Antibodies was a UK-based biotechnology company specializing in the discovery and development of novel antibody therapeutics for chronic inflammatory conditions. The company was acquired by the global biopharmaceutical company AbbVie in October 2022 for approximately $255 million in cash, with potential for additional milestone payments.
How We Help
Problem Statement
The company aimed to develop novel antibody therapeutics for chronic inflammatory conditions, particularly targeting difficult-to-drug G protein-coupled receptor (GPCR) targets and other intractable proteins that traditional methods struggle with.
Core Technology
Proprietary HEPTAD platform, a system designed to discover therapeutic antibodies, especially against difficult-to-drug G protein-coupled receptor (GPCR) targets and other intractable proteins.
Key Differentiators
Proprietary HEPTAD platform for discovering antibodies against difficult-to-drug targets (e.g., GPCRs); specialized focus on chronic inflammatory diseases; established pipeline programs like DJS-002 for IPF and DJS-001 for myeloid cell inflammatory disease.
Clinical Focus
Chronic inflammatory conditions, Idiopathic Pulmonary Fibrosis (IPF), fibrotic diseases, myeloid cell inflammatory disease, diabetic nephropathy.
Target Customers
Biopharmaceutical companies (e.g., AbbVie, who acquired them) for licensing or acquisition of their therapeutic pipeline and technology, with the ultimate goal of benefiting patients.
Product Stage
Beta
Company Info
- Business Model
- B2B (discovery and development of biopharmaceutical assets leading to acquisition by larger pharmaceutical companies)
- Founded
- 2014
- Total Funding
- 36,000,000
- Website
- djsantibodies.com
Categories
Disease Areas
Technologies
Clinical & IP
Clinical Validation
Pipeline includes DJS-002 (LPA receptor 1 antagonist antibody for IPF) and DJS-001 (myeloid cell inflammatory disease), indicating active development of therapeutic candidates.
MedStartr Index Score
?What do you think of DJS Antibodies?
A HUGE part of what early stage companies, and even late stage ones, need and get on MedStartr is honest feedback from actual patients, clinicians, hospital leaders and industry insiders. It is very easy to get tunnel vision as a founder. Please tell the team that runs this company what you think.